Feasibility of de-linking reimbursement of antimicrobials from sales: the Australian perspective as a qualitative case study

摘要

There is a disparity in the economic return achievable for antimicrobials compared with other drugs because of the need for stewardship. This has led to a decline in pharmaceutical companies’ willingness to invest in the development of these drugs and a consequent global interest in funding models where reimbursement is de-linked from sales.